Billion Photos / Shutterstock.com
As lawyers and industry prepare for a possible no-deal Brexit, the uncertainty surrounding its impact runs like a core through the industry, as LSIPR’s Saman Javed discovers.
As the UK’s proposed departure from the EU creeps closer, and a no-deal Brexit—leaving without an agreement as to what the future relationship between the remaining 27 members and the UK will be—looks a very real possibility, there is a growing concern across the country’s life sciences industry about how much this will impact what they do, and how much is still uncertain.
“There is an awful lot of guesswork going on, not only for law firms but also regarding the potential effects on the pharma industry” says Graham Burnett-Hall, a partner at Marks & Clerk in the UK.
Sally Shorthose, a partner at Bird & Bird, says the only thing worse than a no-deal Brexit is not knowing whether there will be one or not.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Brexit, no-deal, life sciences, pharmaceutical industry, innovation, BMA, clinical trials, WTO, tariffs, EAEC, medicines regulation, cancer drugs, EPOm SPC
